Rattle and hum: Roche, PTC post update on their SMA drug as a shaken Biogen faces yet another franchise buster
Right on the heels of Novartis’ latest data on its SMA gene therapy for spinal muscular atrophy, PTC and its partners at Roche/Genentech posted …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
